- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mike Lattanzi: Precision Oncology Options and Increasing Rates of Prostate Cancer
Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.
Mike Lattanzi, MD, genitourinary medical oncologist at Texas Oncology, discusses the use of next-generation sequencing when treating an increasing number of patients with genitourinary diseases.
Transcript
Is payer coverage for genomic testing keeping pace with the precision oncology options in genitourinary disease?
I'm fortunate enough to be able to send next-generation sequencing on virtually all of my patients with metastatic disease. And I routinely send both tissue-based as well as liquid cell-free DNA next-generation sequencing for all patients with metastatic GU [genitourinary] cancers.
The most recent annual report on cancer statistics from the American Cancer Society showed a rise in prostate cancer after years of decline. What are your thoughts on why prostate cancer is increasing?
There's recently been an increase in the incidence of prostate cancer diagnoses as well as a trend toward later-stage diagnoses, which a lot of us feel is due to diminished screening during the COVID-19 pandemic. So, these data are just a reminder to always be screening patients in a guideline-appropriate fashion moving forward.
For Community Oncology, Good News in PFS Offset by Potential Wreckage of MFP Proposal
July 15th 2025CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.
Read More
Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down
June 30th 2025Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.
Read More
